タカダ タクマ   TAKADA Takuma
  髙田 卓磨
   所属   研究施設 研究施設
   職種   非常勤講師
言語種別 英語
発表タイトル Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism in the Era of Direct Oral Anticoagulants: From the COMMAND VTE Registry-2
会議名 第87回日本循環器学会学術集会
学会区分 全国規模の学会
発表形式 口頭
講演区分 一般
発表者・共同発表者Nobutaka Ikeda, Ryuki Chatani, Kazuhisa Kaneda, Yuji Nishimoto, Yohei Kobayashi, Satoshi Ikeda, Kite Kim, Toru Takase, Shuhei Tsuji, Maki Ohi, Takuma Takada, Kazunori Otsui, Jiro Sakamoto, Yoshito Ogihara, Yugo Yamashita
発表年月日 2023/03/10
開催地
(都市, 国名)
福岡
概要 Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is a life-threatening complication after acute pulmonary embolism (PE). The incidence has not been fully evaluated in the era of direct oral anticoagulants (DOACs). Methods: The COMMAND VTE Registry-2 is a multicenter registry enrolling 5197 consecutive acute symptomatic venous thromboembolism patients among 31 centers in Japan. From the database, the incidence of CTEPH was ascertained. COMMAND-CTEPH Risk Score was created based on the results of Cox regression analysis to stratify the risk of development of CTEPH. Results: After a median 747-days follow-up of 2787 acute-PE patients, 48 CTEPH were identified (cumulative incidence 2.4%). There was no significant difference in the incidence of CTEPH between maintenance treatments of DOACs (2.3%) and warfarin (3.7%). Of the acute-PE patients with a Command-CTEPH Risk Score of 4 (maximum), 35.3% developed CTEPH. Conclusions: The cumulative incidence of CTEPH after acute-PE in the DOACs era was 2.4%. Stratification of risk of developing CTEPH may be useful for follow-up of PE.